8-10 November 2024 –

Neomatrix presenting a Poster at SITC’s 39^th Annual Meeting, the leading member-driven organization focused on cancer immunotherapy. At SITC’s Annual Meeting, international leaders from academia, regulatory and government agencies, as well as industry representatives meet for advancing Cancer Immunotherapies.

Our Scientist Ilaria Esposito presents the abstract:

Enhancing Cancer Immunotherapy through Synthetic Biology: A Novel Heterologous Prime-Boost Strategy

Our results show compelling evidence that Neomatrix’ synthetic biology-based heterologous prime-boost strategy is feasible and may offer a valid alternative as immunotherapy platform. 

https://www.linkedin.com/company/72454512/admin/dashboard/